Isis gets $3.5M as antisense drug trial proceeds

05/12/2013 | Genetic Engineering & Biotechnology News

Biogen Idec paid Isis Pharmaceuticals a $3.5 million milestone fee after the dosing of the first infant with spinal muscular atrophy in a midstage trial of the antisense drug ISIS-SMN. The open-label study, which will involve eight infants with the condition, will be carried out in the U.S. and Canada.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN